Halozyme Therapeutics (NASDAQ:HALO) Releases FY24 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $3.55-3.90 for the period, compared to the consensus estimate of $3.52. The company issued revenue guidance of $915-985 million, compared to the consensus revenue estimate of $954.43 million.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $0.35 during midday trading on Tuesday, hitting $41.21. The company’s stock had a trading volume of 1,242,605 shares, compared to its average volume of 1,207,069. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The stock’s 50 day simple moving average is $40.01 and its 200 day simple moving average is $37.94. The stock has a market capitalization of $5.24 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics has a fifty-two week low of $29.85 and a fifty-two week high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. As a group, research analysts anticipate that Halozyme Therapeutics will post 3.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. TheStreet cut shares of Halozyme Therapeutics from a b- rating to a c+ rating in a research note on Monday, January 22nd. StockNews.com raised Halozyme Therapeutics from a hold rating to a buy rating in a research report on Friday, February 23rd. Benchmark reiterated a buy rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. HC Wainwright reaffirmed a buy rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday. Finally, TD Cowen started coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They issued an outperform rating and a $54.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $53.29.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock worth $1,196,800 over the last three months. Company insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.